Standout Papers

Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic <i>BRAF</i> V600–M... 2017 2026 2020 2023 591
  1. Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600–Mutant Anaplastic Thyroid Cancer (2017)
    Vivek Subbiah, Robert J. Kreitman et al. Journal of Clinical Oncology
  2. Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial (2020)
    Vivek Subbiah, Ulrik Lassen et al. The Lancet Oncology
  3. The next generation of evidence-based medicine (2023)
    Vivek Subbiah Nature Medicine
  4. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial (2022)
    Vivek Subbiah, Jürgen Wolf et al. The Lancet Oncology
  5. Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers (2021)
    Matteo Palmeri, Janice M. Mehnert et al. ESMO Open
  6. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study (2022)
    Vivek Subbiah, Robert J. Kreitman et al. Annals of Oncology
  7. Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial (2022)
    Vivek Subbiah, Philippe A. Cassier et al. Nature Medicine
  8. Selpercatinib in Patients With RET Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial (2022)
    Alexander Drilon, Vivek Subbiah et al. Journal of Clinical Oncology
  9. Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges (2023)
    Giannis Mountzios, Jordi Remón et al. Nature Reviews Clinical Oncology

Immediate Impact

2 by Nobel laureates 19 from Science/Nature 62 standout
Sub-graph 1 of 23

Citing Papers

A foundation model of transcription across human cell types
2025 StandoutNature
Artificial intelligence in drug development
2025 Standout
1 intermediate paper

Works of Vivek Subbiah being referenced

The next generation of evidence-based medicine
2023 Standout
Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy
2016

Author Peers

Author Last Decade Papers Cites
Vivek Subbiah 5741 4501 3026 3560 583 11.6k
Aung Naing 5706 2918 2986 4345 477 12.1k
Anthony J. Gill 5586 4224 3577 4359 527 16.3k
Bhumsuk Keam 5905 3935 1533 2090 367 9.6k
Ezra E.W. Cohen 8308 5492 1956 4585 416 16.4k
Patrick Schöffski 9407 9276 2187 4736 500 18.9k
Sabino De Placido 7699 4412 3698 4332 376 13.7k
Roger B. Cohen 9018 5780 1845 5350 320 17.1k
Yoshitaka Fujii 8242 8943 3917 7574 436 19.6k
Adam Brufsky 9714 5141 4426 3138 494 15.6k
Emilio Bajetta 10203 5759 3604 3860 323 16.3k

All Works

Loading papers...

Rankless by CCL
2026